Home
overview
Dear Pharmaceutical Executive

I am delighted to recommend to you the forthcoming SMi conference on Angiogenesis and Antiangiogenesis Therapeutics. I have agreed to co-Chair this major event because of the growing momentum of the angiogenesis field, and the information needs that have been generated. The high level speakers will provide both range and depth of expert opinion to conference delegates.

Angiogenesis and Antiangiogenesis Therapeutics aims to explore the current advances in drug discovery, pre-clinical developments, clinical trial advances, and drug delivery technologies. As you may know, these issues form the basis for continuing progress in angiogenesis drug development. Both inhibitors and stimulators will be covered in this meeting, as well as topics of imaging and non-surgical cardiovascular gene therapy. It will undoubtedly appeal to senior managers and directors from pharmaceutical and biotechnology companies, drug delivery companies and clinical research organisations.

The Angiogenesis Foundation is pleased to endorse this conference which will be held on 20th & 21st February in London. The conference has been organised specifically to bring together leading senior executives with focused and timely information. I am sure you will agree the event will keep you abreast of all the latest developments in angiogenesis therapeutics.

I look forward to seeing you there in February.

William W. Li, M.D.
President and Medical Director
The Angiogenesis Foundation

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr William Li

Dr William Li, President & Medical Director, The Angiogenesis Foundation

9:10 VEGF

Dr Hanspeter Gerber

Dr Hanspeter Gerber, Scientist, Genentech

  • Recent advances in therapeutic Mab’s in oncology
  • Data update: neutralising antibody against VEGF (Avastin)
  • Development: anti-VEGF and bone growth
  • Tumour models: anti-VEGF and tumour growth
  • How does VEGF regulate hematopoiesis?
  • Update on the phase II and III clinical data using Avastin
  • 9:40 INVESTIGATION OF NOVEL ANGIOGENESIS INHIBITORS

    Dr Jeffery Robinson

    Dr Jeffery Robinson, Chairman, BioActa

  • Discovery and development of novel anti-angiogenic therapeutics
  • Role of polypeptide and peptide inhibitors
  • Fibrin-E and fibrinogen-E fragments
  • Alphastatin™ - a novel peptide inhibitor
  • Applications of peptide inhibitors
  • 10:20 TUMOUR ANGIOGENESIS

    Dr Francesc Mitjans

    Dr Francesc Mitjans, Project Leader, Merck Farma y Quimica

  • Cell adhesion molecules
  • Alpha-v integrins and tumour angiogenesis
  • Research developments
  • In vivo tumour models
  • Results from pre-clinical studies
  • Future developments
  • 11:00 Morning Coffee

    11:20 ANTI-ANGIOGENESIS TREATMENTS

    Dr James Winkler

    Dr James Winkler, Associate Director, Oncology, GlaxoSmithKline

  • Traditional cancer treatment vs angiogenesis inhibitors
  • Treatment models
  • Lessons from early trials
  • Research and development of angiogenesis-based medicines
  • 12:00 R&D OF ANTI-ANGIOGENIC AGENTS AT ENTREMED

    Dr Tony Treston

    Dr Tony Treston, Associate Director, Discovery Research Department, EntreMed

  • Clinical update on Entremend’s anti-angiogenic drug candidates
  • Thalidomide as an anti-angiogenic agent
  • Selection of 'next generation' chemical analogs of thalidomide
  • Results from pre-clinical studies
  • Other new anti-angiogenic agents in development at EntreMed
  • 12:40 Lunch

    13:40 ANGIOGENESIS DRUG DEVELOPMENT

    Dr Pierre Champagne

    Dr Pierre Champagne, Senior Director, Clinical Research, AEterna Laboratories

  • Pleiotropic activity of Neovastat
  • Exploring Neovastat in different types of tumours
  • Increasing survival time of patients
  • Aims of phase III trials
  • Current status of phase III trials
  • Taking the product to the market
    Predictions for Neovastat
  • 14:20 TARGETING ANGIOGENESIS WITH ANTI-ANGIOGENIC AND CYTOTOXIC DRUGS COMBINED IN SINGLE THERAPEUTIC ENTITIES USING SELF-ASSEMBLED COLLOID COMPOSITIONS

    Dr Valery Alakhov

    Dr Valery Alakhov, Vice President Research & Development & Chief Scientist, Supratek Pharma

  • Flt-1 receptor as a target for anti-angiogenesis drugs
  • SP5.2 - a Flt-1 receptor specific VEGF antagonist
  • Block copolymer self-assembled compositions - a combinatorial platform for multi-valent display of single and combined therapies
  • Block copolymer compositions of SP5.2 and cytotoxic drugs (paclitaxel; anthracyclines and platinum complexes), in vivo and in vitro results
  • Further development steps and potential clinical applications
  • 15:00 Afternoon Tea

    15:20 COMMERCIALISATION OF THALIDOMIDE ANALOGS

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Executive Vice President, Pharm R&D, Celgene

  • Selection of 'next generation' chemical analogs of thalidomide
  • Results from pre-clinical studies
  • Patent claims and building an intellectual property portfolio
  • Selection of drug candidates for further trials
  • Development and commercialisation partnerships
  • Towards commercialisation
  • 16:00 TARGETING TUMOUR VASCULATURE

    Dr Alan Barge

    Dr Alan Barge, Global Product Director, AstraZeneca

  • Pre-clinical issues
  • Clinical issues
  • Challenges in development
  • Future perspectives
  • 16:40 VASCULAR TARGETING AGENTS (VTAs)

    Dr David Chaplin

    Dr David Chaplin, Chief Scientific Officer & Head of Research & Development, Oxigene

  • Comparing vascular targeting with anti-angiogenic approaches
  • Tubulin depolymersing agents as neovascular damaging agents
  • Combretastatin A4 phosphate: preclinical and clinical experience
  • Future directions for VTA development
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Phillip C. Thomas

    Dr Phillip C. Thomas, Chief Executive Officer, DOBI Medical Systems

    9:10 ANALYSIS OF ANGIOGENIC AND ANTI-ANGIOGENIC CLINICAL STRATEGIES

    Dr William Li

    Dr William Li, President & Medical Director, The Angiogenesis Foundation

  • Current global status of angiogenesis-based clinical development
  • Paradigm shifts in clinical trial design and evaluation
  • Long-term considerations for angiogenesis-based therapies: physiology and pathology
  • Key success factors for commercialisation
  • New R&D opportunities
  • Long term market prospects
  • 9:40 ANGIOGENESIS IMAGING

    Dr King Li

    Dr King Li, Associate Director for Imaging Science Programme and Diagnostic Radiology, US National Institute of Health

  • Current imaging technologies for cancer detection
  • Developing an angiogenesis based diagnostic system cancer detection
  • Complying with the European Union’s Medical Device Directive
  • Process compliance
  • Clinical trials and market usage
  • 10:20 ANGIOGENESIS DRUG DISCOVERY

    Dr Camila Esguerra

    Dr Camila Esguerra, Vice President Research, Mermaid Pharmaceuticals

  • Use of in organismo bioassays and morpholino antisense technology
  • Large-scale gene functionation
  • New targets for applications in angiogenesis and anti-angiogenesis
  • New in organismo disease models for validation of targets and compounds
  • Discovery and development of small molecules, antibodies and proteins
  • 11:00 Morning Coffee

    11:20 POSSIBLE MECHANISMS OF ANGIOGENESIS INHIBITION

    Dr Surender Kharbanda

    Dr Surender Kharbanda, Senior Director, Research and Development, Ilex Oncology

  • In vivo cancer models
  • Small molecule inhibitors
  • Mechanism of action
  • Synergy with chemo and radio therapy
  • 12:00 EVALUATING THE POTENTIAL OF THE ANGIOPOIETINS AND VEGF AS TARGETS FOR CANCER THERAPY

    Dr Jocelyn Holash

    Dr Jocelyn Holash, Associate Director, Tumor Angiogenesis, Regeneron Pharmaceuticals

  • VEGF and the Angiopoietins play unique yet cooperative roles in angiogenesis
  • Angiopoietins-2 is highly upregulated in tumor blood vessels
  • VEGF promotess angiogenesis within tumors
  • Regeneron’s 'VEGF-Trap' is a novel anti-angiogenic agent which potently blocks angiogenesis and inhibits tumor growth in animal models of cancer
  • 12:40 Lunch

    14:00 GENOMICS-BASED APPROACHES TO IDENTIFY AND VALIDATE NOVEL ANGIOGENIC FACTORS

    Dr John Herrmann

    Dr John Herrmann, Project Leader, Oncology Program, CuraGen

  • A case for directed therapeutic targeting of the targeting of the tumor endothelium
  • Hypoxia is a driving force for early stage tumor and metastasis formation
  • Hypoxia/Hif-1x microvessel endothelial cell knockout model system for novel target discovery
  • Characterisation of a novel angiopoietin identified through sequence database mining
  • Tumor endothelial markers (TEMs) as mAb targets
  • Pathways regulated by hypoxia and oxygen
    Managing and controlling cancer
  • 14:40 CONSIDERATIONS IN DEVELOPMENT OF ANGIOGENIC GENE THERAPIES

    Dr Michael Coleman

    Dr Michael Coleman, Director, Cardiovascular Product Discovery, Valentis

  • Choice of therapeutic gene
  • Pharmacokinetics, biodistribution and choice of delivery system
  • Temporal and cell-specific reulation of transgene expression to improve safety
  • Percutaneous retrograde delivery of angiogenic gene therapy in CAD
  • Experience in clinical trials
  • 15:20 Afternoon Tea

    15:40 VECTOR-MEDIATED TRANSFER OF GENES FOR ANGIOGENIC FACTORS

    Dr Mitchell Finer

    Dr Mitchell Finer, Vice President & Worldwide Head of Preclinical Research, Gencell

  • Growing new blood vessels in the heart and lungs
  • Developing a gene delivery system
  • Replace or augment bypass surgery?
  • Results of clinical trials
  • Will it work?
  • 16:20 DEVELOPMENT OF NON-SURGICAL CARDIOVASCULAR GENE THERAPY

    Dr Christopher Reinhard

    Dr Christopher Reinhard, President, Collateral Therapeutics

  • Importance of identifying gene
  • Leverage of commercial value
  • Development of gene therapy products
  • Uses in cardiovascular diseases
  • Combining VEGF and FGF proteins in ‘dual recombinants’
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Angiogenesis Imaging
    Workshop

    Angiogenesis Imaging

    The Hatton, at etc. venues
    22nd February 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.